Product Development
GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute
Plus SAB gets additional funding from U.S. government, starts human trials
Aug 13, 2020 | 1:48 AM GMT
GigaGen is developing polyclonal antibodies for COVID-19 and
